A Phase 1 interventional study of WVE-006 in Alpha-1 Antitrypsin Deficiency (AATD), sponsored by Wave Life Sciences USA, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Wave Life Sciences USA, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom — 8 open to participants now, 11 under way, 3 of them phase 3. alpha 1-Antitrypsin Deficiency · United Kingdom.
Among the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2023, is one of 7 in phase 1, and was the 20th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →8 of the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom are open now. Recruiting first, the newest first:
Richmond Research Institute · Sites in United Kingdom
Ages 18+
Tessera Therapeutics, Inc. · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 18–70
AIRNA Corporation · Sites in United Kingdom, Australia, Georgia and 6 more countries
Ages 18–74
Takeda · Sites in United Kingdom, United States, Austria and 3 more countries
Ages 18+
Wave Life Sciences USA, Inc. · Sites in United Kingdom, Australia, Canada and 3 more countries
Ages 18–70
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 6
First in 2003; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is above the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 54 across the 25 interventional studies, 500 across the 3 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 28 have an industry lead sponsor. The 10 most frequent:
Wave Life Sciences USA, Inc. is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Wave Life Sciences USA, Inc. has 2 studies filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07924462Richmond Research InstituteChronic Respiratory Disease Participant Engagement Study | 2027-08-01 |
| NCT06405633Wave Life Sciences USA, Inc.A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is the first study in the RestorAATion clinical program.
The purpose of this first-in human (FIH), double-blind, randomized, placebo-controlled, single ascending dose (SAD) and multiple-dose Phase 1 study is to assess the safety, tolerability, and pharmacokinetics (PK) of WVE-006 compared to placebo in healthy participants following a single dose (Period 1) and multiple doses (Period 2) of WVE-006.
This information will be used to determine doses and regimes that have the potential to be pharmacologically active in patients with Alpha-1 antitrypsin deficiency in the RestorAATion 2 study, and the maximum safe and tolerable dose that may be given to these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: WVE-006
Drug: WVE-006
Drug: WVE-006
Drug: WVE-006
Drug: WVE-006
Drug: WVE-006
RNA editing oligonucleotide
The Proportion of Participants With Adverse Events
The number of participants who reported an adverse event (AE) will be summarised.
Time frame: Adverse events are collected from the date of consent until up to 85 days after the dose in Period 1 and up to 113 days after the first dose in Period 2.
Single Ascending Dose (Period 1) - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast)
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 1 of the study.
Time frame: Samples collected at the following timepoints: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr & 12 hr post-Day 1 dose, Day 2: 24 hr & 36 hr post-Day 1 dose, Day 3: 48 hr post-Day 1 dose, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 & 85.
Single Ascending Dose - Maximum Concentration of WVE-006 in Plasma (Cmax)
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 1 of the study.
Time frame: Samples collected at the following timepoints: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr & 12 hr post-Day 1 dose, Day 2: 24 hr & 36 hr post-Day 1 dose, Day 3: 48 hr post-Day 1 dose, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 & 85.
Multiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 1
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 2 of the study.
Time frame: Samples collected at the following timepoints for Day 1 measurement: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.
Multiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 1
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 2 of the study.
Time frame: Samples collected at the following timepoints for Day 1 measurement: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.
Multiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 29
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 2 of the study.
Time frame: Samples collected at the following timepoints for Day 29 measurement: Day 29 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.
Multiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 29
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 2 of the study.
Time frame: Samples collected at the following timepoints for Day 29 measurement: Day 29 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.
Study recruitment was undertaken at one site in the United Kingdom. The recruitment process began in November 2023 and concluded in October 2024. A sufficient number of volunteers were screened in order to successfully recruit 46 completing participants (with one participant withdrawal).
| Milestone | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W |
|---|---|---|---|---|---|---|---|---|
| Started | 10 | 6 | 5 | 6 | 6 | 6 | 6 | 2 |
| Completed | 10 | 6 | 5 | 6 | 6 | 5 | 6 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
The number of participants who reported an adverse event (AE) will be summarised.
| Participants | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W |
|---|---|---|---|---|---|---|---|---|
| The Proportion of Participants With Adverse Events | 8 | 5 | 4 | 3 | 3 | 3 | 2 | 1 |
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 1 of the study.
| h*ng/mL | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg |
|---|---|---|---|---|---|
| Single Ascending Dose (Period 1) - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) | 626 ± 115 | 1978 ± 357 | 7507 ± 4427 | 29466 ± 10688 | 53342 ± 13166 |
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 1 of the study.
| ng/mL | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg |
|---|---|---|---|---|---|
| Single Ascending Dose - Maximum Concentration of WVE-006 in Plasma (Cmax) | 40.4 ± 11.6 | 112 ± 42.2 | 562 ± 440 | 2038 ± 864 | 3718 ± 963 |
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 2 of the study.
| h*ng/mL | Period 2 Cohort 1 - WVE-006 600 mg Q2W |
|---|---|
| Multiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 1 | 75678 ± 44053 |
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 2 of the study.
| ng/mL | Period 2 Cohort 1 - WVE-006 600 mg Q2W |
|---|---|
| Multiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 1 | 5929 ± 4933 |
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 2 of the study.
| h*ng/mL | Period 2 Cohort 1 - WVE-006 600 mg Q2W |
|---|---|
| Multiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 29 | 75824 ± 44437 |
Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 2 of the study.
| ng/mL | Period 2 Cohort 1 - WVE-006 600 mg Q2W |
|---|---|
| Multiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 29 | 5995 ± 5419 |
Collected over Adverse events were reported through ad hoc reporting from the participants from the point of signature of informed consent through to study completion (up to 85 days in Period 1 and up to 113 days in Period 2).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Pooled Placebo | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Period 1 Cohort 1 - WVE-006 30 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Period 1 Cohort 2 - WVE-006 100 mg | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Period 1 Cohort 3 - WVE-006 200 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Period 1 Cohort 4 - WVE-006 400 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Period 1 Cohort 5 - WVE-006 600 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Period 2 Cohort 1 - WVE-006 600 mg Q2W | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Period 2 Cohort 1 - Placebo Q2W | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Event | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W |
|---|---|---|---|---|---|---|---|---|
| Skin AbrasionSkin and subcutaneous tissue disorders | 0/10 | 0/6 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 1/2 |
| Blood Creatinine Phosphokinase IncreasedInvestigations | 1/10 | 1/6 | 2/5 | 0/6 | 0/6 | 1/6 | 0/6 | 0/2 |
| RashSkin and subcutaneous tissue disorders | 1/10 | 1/6 | 2/5 | 1/6 | 0/6 | 0/6 | 0/6 | 0/2 |
| Transaminases IncreasedInvestigations | 1/10 | 1/6 | 2/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 |
| Influenza like IllnessInfections and infestations | 1/10 | 0/6 | 0/5 | 0/6 | 1/6 | 2/6 | 2/6 | 0/2 |
| NasopharyngitisInfections and infestations | 2/10 | 2/6 | 1/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 |
| HeadacheNervous system disorders | 2/10 | 1/6 | 0/5 | 0/6 | 1/6 | 1/6 | 1/6 | 0/2 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/10 | 0/6 | 1/5 | 0/6 | 0/6 | 0/6 | 1/6 | 0/2 |
| ToothacheInjury, poisoning and procedural complications | 0/10 | 0/6 | 1/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 |
| Abdominal DiscomfortGastrointestinal disorders | 0/10 | 1/6 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 |
This analysis population included all 47 enrolled participants.
| Age, Categorical(Participants) | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 6 | 5 | 6 | 6 | 6 | 6 | 2 | 47 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(Years) | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 35.8 ± 9.0 | 34.0 ± 8.7 | 44.4 ± 11.9 | 34.0 ± 10.2 | 36.8 ± 9.3 | 34.8 ± 8.9 | 39.0 ± 12.1 | 39.5 ± 7.8 | 36.4 ± 9.5 |
| Sex: Female, Male(Participants) | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 4 | 0 | 4 | 2 | 2 | 1 | 1 | 18 |
| Male | 6 | 2 | 5 | 2 | 4 | 4 | 5 | 1 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 10 | 6 | 4 | 6 | 6 | 6 | 6 | 2 | 46 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 10 | 6 | 5 | 6 | 6 | 6 | 4 | 1 | 44 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|
| United Kingdom | 10 | 6 | 5 | 6 | 6 | 6 | 6 | 2 | 47 |
| Weight(Kilograms) | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 77.57 ± 11.61 | 82.38 ± 14.75 | 89.60 ± 8.78 | 65.40 ± 10.88 | 73.95 ± 8.45 | 82.45 ± 9.59 | 74.10 ± 16.61 | 91.20 ± 28.43 | 78.17 ± 12.54 |
| Height(Metres) | Period 1: Pooled Placebo | Period 1 Cohort 1 - WVE-006 30 mg | Period 1 Cohort 2 - WVE-006 100 mg | Period 1 Cohort 3 - WVE-006 200 mg | Period 1 Cohort 4 - WVE-006 400 mg | Period 1 Cohort 5 - WVE-006 600 mg | Period 2 Cohort 1 - WVE-006 600 mg Q2W | Period 2 Cohort 1 - Placebo Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 1.740 ± 0.103 | 1.678 ± 0.113 | 1.792 ± 0.064 | 1.677 ± 0.078 | 1.722 ± 0.083 | 1.742 ± 0.037 | 1.748 ± 0.100 | 1.770 ± 0.184 | 1.725 ± 0.089 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Feb 2025, 14 months.
Results were first posted in Mar 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
alpha 1-Antitrypsin Deficiency →
Wave Life Sciences USA, Inc.